| Dr David D Meder, DC | |
|
12 Case St, Suite 312, Norwich, CT 06360-2222 | |
| (860) 887-4325 | |
| (860) 823-1426 |
| Full Name | Dr David D Meder |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 28 Years |
| Location | 12 Case St, Norwich, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083603559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 001434 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Thames Chiropractic Center, P.c. | 8921908617 | 3 |
News Archive
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
The first phase of a caloric restriction study in human subjects at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University found evidence suggesting that calorie-restricted diets differing substantially in glycemic load can result in comparable long-term weight loss.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
Initiated by Professor Yeung Chung-Kwong (Prof Yeung), Honorary Clinical Professor, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, a team of experienced engineers led by Professor Yung Kai-Leung (Prof Yung), Professor and Associate Head of the Department of Industrial and Systems Engineering of The Hong Kong Polytechnic University was invited to develop the system as an engineering partner since 2012.
Peptides that target blood vessels in fat and cause them to go into programmed cell death (termed apoptosis) could become a model for future weight-loss therapies, say University of Cincinnati (UC) researchers.
› Verified 9 days ago
| Provider Name | Thames Chiropractic Center, P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518086164 PECOS PAC ID: 8921908617 Enrollment ID: O20040109000758 |
News Archive
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
The first phase of a caloric restriction study in human subjects at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University found evidence suggesting that calorie-restricted diets differing substantially in glycemic load can result in comparable long-term weight loss.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
Initiated by Professor Yeung Chung-Kwong (Prof Yeung), Honorary Clinical Professor, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, a team of experienced engineers led by Professor Yung Kai-Leung (Prof Yung), Professor and Associate Head of the Department of Industrial and Systems Engineering of The Hong Kong Polytechnic University was invited to develop the system as an engineering partner since 2012.
Peptides that target blood vessels in fat and cause them to go into programmed cell death (termed apoptosis) could become a model for future weight-loss therapies, say University of Cincinnati (UC) researchers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David D Meder, DC 12 Case St, Suite 312, Norwich, CT 06360-2222 Ph: (860) 887-4325 | Dr David D Meder, DC 12 Case St, Suite 312, Norwich, CT 06360-2222 Ph: (860) 887-4325 |
News Archive
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
The first phase of a caloric restriction study in human subjects at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University found evidence suggesting that calorie-restricted diets differing substantially in glycemic load can result in comparable long-term weight loss.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
Initiated by Professor Yeung Chung-Kwong (Prof Yeung), Honorary Clinical Professor, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, a team of experienced engineers led by Professor Yung Kai-Leung (Prof Yung), Professor and Associate Head of the Department of Industrial and Systems Engineering of The Hong Kong Polytechnic University was invited to develop the system as an engineering partner since 2012.
Peptides that target blood vessels in fat and cause them to go into programmed cell death (termed apoptosis) could become a model for future weight-loss therapies, say University of Cincinnati (UC) researchers.
› Verified 9 days ago
Dr. Paul E Sayour, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 85 Sachem St, Norwich, CT 06360 Phone: 860-889-5812 Fax: 860-886-9247 | |
Dr. James Alan Eckert, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 598 W Main St, Suite One, Norwich, CT 06360 Phone: 860-889-1475 Fax: 860-889-2850 | |
Dr. Cheryl Chao Blankenship, D.C. L.AC. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 148 Sachem St, Norwich, CT 06360 Phone: 860-886-2882 Fax: 860-886-6886 | |
Dr. Christopher Andrew Macadam, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 12 Case St, Suite 312, Norwich, CT 06360 Phone: 860-887-4325 Fax: 860-823-1426 | |
Devon Sara Elizabeth Mann, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 12 Case St, 312, Norwich, CT 06360 Phone: 860-887-4325 Fax: 860-823-1426 | |
Dr. Carl Zapatka, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 12 Case St, Suite 312, Norwich, CT 06360 Phone: 860-887-4325 Fax: 860-823-1426 |